Filter By Category
Archives
Share on -
EDRALBRUTINIB
Generic Name: EDRALBRUTINIB
ABSTRACT -
Edralbrutinib is a BTK-inhibitor API candidate. BTK inhibition affects B-cell receptor signaling and may be used in autoimmune or hematologic oncology contexts.
DOSAGE -
Oral study dosing is protocol-specific. Monitor for class-related bleeding, infection, cardiac, and liver effects.
SIDE EEFECTS -
- Diarrhea or nausea
- Headache
- Rash
- Infections
- Bleeding or bruising
ALLERGIC REACTIONS -
These symptoms may indicate an allergic reaction and require medical attention.
- Rash, urticaria, angioedema, bronchospasm, or anaphylaxis
DRUG INTEACTIONS-
- Strong CYP3A inhibitors/inducers may affect exposure for many BTK inhibitors
- Anticoagulants or antiplatelets may increase bleeding risk
- Other immunosuppressants may increase infection risk
PREAUTONS–
- Monitor CBC, infections, bleeding, blood pressure, and cardiac rhythm symptoms
- Hold around procedures if protocol requires
- Use contraception and pregnancy precautions
WARNINGS –
- Serious bleeding, infection, cytopenias, arrhythmias, and embryo-fetal harm may occur with BTK inhibitors
Share on -
. Developed by